Cargando…
AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells
BACKGROUND: Mesenchymal stromal cell (MSC) stemness capacity diminishes over prolonged in vitro culture, which negatively affects their application in regenerative medicine. To slow down the senescence of MSCs, here, we have evaluated the in vitro effects of 5-aminoimidazole-4-carboxamide ribonucleo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998366/ https://www.ncbi.nlm.nih.gov/pubmed/32014016 http://dx.doi.org/10.1186/s13287-020-1565-6 |
_version_ | 1783493839057584128 |
---|---|
author | Khorraminejad-Shirazi, Mohammadhossein Sani, Mahsa Talaei-Khozani, Tahereh Dorvash, Mohammadreza Mirzaei, Malihe Faghihi, Mohammad Ali Monabati, Ahmad Attar, Armin |
author_facet | Khorraminejad-Shirazi, Mohammadhossein Sani, Mahsa Talaei-Khozani, Tahereh Dorvash, Mohammadreza Mirzaei, Malihe Faghihi, Mohammad Ali Monabati, Ahmad Attar, Armin |
author_sort | Khorraminejad-Shirazi, Mohammadhossein |
collection | PubMed |
description | BACKGROUND: Mesenchymal stromal cell (MSC) stemness capacity diminishes over prolonged in vitro culture, which negatively affects their application in regenerative medicine. To slow down the senescence of MSCs, here, we have evaluated the in vitro effects of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an AMPK activator, and nicotinamide (NAM), an activator of sirtuin1 (SIRT1). METHODS: Human adipose-derived MSCs were cultured to passage (P) 5. Subsequently, the cells were grown in either normal medium alone (control group), the medium supplemented with AICAR (1 mM) and NAM (5 mM), or in the presence of both for 5 weeks to P10. Cell proliferation, differentiation capacity, level of apoptosis and autophagy, morphological changes, total cellular reactive oxygen species (ROS), and activity of mTORC1 and AMPK were compared among different treatment groups. RESULTS: MSCs treated with AICAR, NAM, or both displayed an increase in proliferation and osteogenic differentiation, which was augmented in the group receiving both. Treatment with AICAR or NAM led to decreased expression of β-galactosidase, reduced accumulation of dysfunctional lysosomes, and characteristic morphologic features of young MSCs. Furthermore, while NAM administration could significantly reduce the total cellular ROS in aged MSCs, AICAR treatment did not. Moreover, AICAR-treated cells possess a high proliferation capacity; however, they also show the highest level of cellular apoptosis. The observed effects of AICAR and NAM were in light of the attenuated mTORC1 activity and increased AMPK activity and autophagy. CONCLUSIONS: Selective inhibition of mTORC1 by AICAR and NAM boosts autophagy, retains MSCs’ self-renewal and multi-lineage differentiation capacity, and postpones senescence-associated changes after prolonged in vitro culture. Additionally, co-administration of AICAR and NAM shows an additive or probably a synergistic effect on cellular senescence. |
format | Online Article Text |
id | pubmed-6998366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69983662020-02-10 AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells Khorraminejad-Shirazi, Mohammadhossein Sani, Mahsa Talaei-Khozani, Tahereh Dorvash, Mohammadreza Mirzaei, Malihe Faghihi, Mohammad Ali Monabati, Ahmad Attar, Armin Stem Cell Res Ther Research BACKGROUND: Mesenchymal stromal cell (MSC) stemness capacity diminishes over prolonged in vitro culture, which negatively affects their application in regenerative medicine. To slow down the senescence of MSCs, here, we have evaluated the in vitro effects of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an AMPK activator, and nicotinamide (NAM), an activator of sirtuin1 (SIRT1). METHODS: Human adipose-derived MSCs were cultured to passage (P) 5. Subsequently, the cells were grown in either normal medium alone (control group), the medium supplemented with AICAR (1 mM) and NAM (5 mM), or in the presence of both for 5 weeks to P10. Cell proliferation, differentiation capacity, level of apoptosis and autophagy, morphological changes, total cellular reactive oxygen species (ROS), and activity of mTORC1 and AMPK were compared among different treatment groups. RESULTS: MSCs treated with AICAR, NAM, or both displayed an increase in proliferation and osteogenic differentiation, which was augmented in the group receiving both. Treatment with AICAR or NAM led to decreased expression of β-galactosidase, reduced accumulation of dysfunctional lysosomes, and characteristic morphologic features of young MSCs. Furthermore, while NAM administration could significantly reduce the total cellular ROS in aged MSCs, AICAR treatment did not. Moreover, AICAR-treated cells possess a high proliferation capacity; however, they also show the highest level of cellular apoptosis. The observed effects of AICAR and NAM were in light of the attenuated mTORC1 activity and increased AMPK activity and autophagy. CONCLUSIONS: Selective inhibition of mTORC1 by AICAR and NAM boosts autophagy, retains MSCs’ self-renewal and multi-lineage differentiation capacity, and postpones senescence-associated changes after prolonged in vitro culture. Additionally, co-administration of AICAR and NAM shows an additive or probably a synergistic effect on cellular senescence. BioMed Central 2020-02-03 /pmc/articles/PMC6998366/ /pubmed/32014016 http://dx.doi.org/10.1186/s13287-020-1565-6 Text en © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Khorraminejad-Shirazi, Mohammadhossein Sani, Mahsa Talaei-Khozani, Tahereh Dorvash, Mohammadreza Mirzaei, Malihe Faghihi, Mohammad Ali Monabati, Ahmad Attar, Armin AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title | AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title_full | AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title_fullStr | AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title_full_unstemmed | AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title_short | AICAR and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
title_sort | aicar and nicotinamide treatment synergistically augment the proliferation and attenuate senescence-associated changes in mesenchymal stromal cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998366/ https://www.ncbi.nlm.nih.gov/pubmed/32014016 http://dx.doi.org/10.1186/s13287-020-1565-6 |
work_keys_str_mv | AT khorraminejadshirazimohammadhossein aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT sanimahsa aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT talaeikhozanitahereh aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT dorvashmohammadreza aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT mirzaeimalihe aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT faghihimohammadali aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT monabatiahmad aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells AT attararmin aicarandnicotinamidetreatmentsynergisticallyaugmenttheproliferationandattenuatesenescenceassociatedchangesinmesenchymalstromalcells |